The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial
Abstract
PURPOSE: We evaluated the use of botulinum toxin-A in treating patients with idiopathic detrusor overactivity refractory to anticholinergics. MATERIALS AND METHODS: This double-blind, placebo controlled trial randomized participants to intradetrusor injections of 200 U botulinum toxin-A (16 patients) or placebo (18 patients). The primary outcome measure was change in maximum cystometric capacity. Secondary outcome measures included changes in overactive bladder symptoms, post-void residual, maximum detrusor pressure during filling cystometry and reflex detrusor volume. Quality of life was assessed using the Incontinence Impact Questionnaire short form 7 and Urogenital Distress Inventory short form 6. Followup occurred at 4 and 12 weeks after injection, at which point the study was unblinded. Further followup in the botulinum toxin-A group occurred at 24 weeks. RESULTS: Significant increases in maximum cystometric capacity were observed at 4 weeks (difference 144.69 ml, 95% CI 100.95 to 215.75, p <0.0001) and 12 weeks (difference 95.71 ml, 95% CI 47.47 to 172.45, p = 0.001) in patients treated with botulinum toxin-A compared to placebo. Botulinum toxin-A reduced frequency (p <0.001, p = 0.003) and urgency urinary incontinence (p = 0.03, p = 0.008) episodes at 4 and 12 weeks, respectively. Urgency was reduced at 4 weeks (p = 0.005) in the botulinum toxin-A group. In patients receiving botulinum toxin-A, post-void residual increased at 4 weeks (p = 0.024) but became insignificant by 12 weeks (p = 0.406). Of these patients 6 required intermittent self-catheterization. Significant improvements in quality of life were observed following botulinum toxin-A. The extension study suggests that the beneficial effects of botulinum toxin-A are maintained for at least 24 weeks. CONCLUSIONS: Botulinum toxin-A at 200 U is safe and effective for idiopathic detrusor overactivity and the beneficial effects persist for at least 24 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., & Wein, A. (2002) · Neurourology and Urodynamics · doi:10.1002/nau.10052 · Cited by 8,296
Abrams, P., Blaivas, J. G., Stanton, S. L., & Andersen, J. T. (1989) · World Journal of Urology · doi:10.1007/bf00328107 · Cited by 1,795
Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure‐flow studies**
Schäfer, W., Abrams, P., Liao, L., Mattiasson, A., Pesce, F., Spangberg, A., Sterling, A. M., Zinner, N. R., & Kerrebroeck, P. V. (2002) · Neurourology and Urodynamics · doi:10.1002/nau.10066 · Cited by 1,742
SCHURCH, B., STÖHRER, M., KRAMER, G., SCHMID, D. M., GAUL, G., & HAURI, D. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67283-7 · Cited by 822
Schurch, B., de Sèze, M., Denys, P., Chartier-Kastler, E. J., Haab, F., Everaert, K., Plante, P., Perrouin-Verbe, B., KUMAR, C., Fraczek, S., et al. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000162035.73977.1c · Cited by 568
Apostolidis, A., Dasgupta, P., & Fowler, C. J. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.010 · Cited by 347
Self-citationHarper, M., Popat, R., Dasgupta, R., et al. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04312.x · Cited by 114
Cited by
Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., et al. (2012) · Journal of Urology · doi:10.1016/j.juro.2012.09.079 · Cited by 710
Nitti, V. W., Dmochowski, R., Herschorn, S., Sand, P., Thompson, C., Nardo, C., Yan, X., Haag-Molkenteller, C., & EMBARK Study Group (2013) · Journal of Urology · doi:10.1016/j.juro.2012.12.022 · Cited by 413
Dmochowski, R., Chapple, C., Nitti, V. W., Chancellor, M., Everaert, K., Thompson, C., Daniell, G., Zhou, J., & Haag-Molkenteller, C. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.08.021 · Cited by 406
Nitti, V. W., Dmochowski, R., Herschorn, S., Sand, P., Thompson, C., Nardo, C., Yan, X., Haag-Molkenteller, C., & EMBARK Study Group S0022534716316627-20351d5d064fd7a57fb97540a9795212 C. Andreou, S.-1. R. B. E. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.109 · Cited by 330
Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection
Brubaker, L., Richter, H. E., Visco, A., Mahajan, S., Nygaard, I., Braun, T. M., Barber, M. D., Menefee, S., Schaffer, J., Weber, A. M., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.03.028 · Cited by 328
Metadata
- Authors
- Sahai, A., Khan, M. S., Dasgupta, P., & GKT Botulinum Study Group
- Venue
- Journal of Urology
- Published
- 2007-06
- Volume
- 177
- Issue
- 6
- Pages
- 2231-2236
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2079232828
- Cited by
- 312
- References
- 7
- FWCI
- 33.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial. https://app.cochat.ai/papers/10.1016/j.juro.2007.01.130
- The paper
- Sahai, A., Khan, M. S., Dasgupta, P., & GKT Botulinum Study Group. (2007). Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial. Journal of Urology. https://doi.org/10.1016/j.juro.2007.01.130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.